What Intuitive Surgical’s recent share performance means for investors

Intuitive Surgical (ISRG) has seen mixed share performance recently, with a 4.0% gain over the past month, a 10.3% decline over the past 3 months, and an 8.4% drop over the past year.

In this context, the company reports annual revenue of US$10.58b and net income of US$2.98b, with both metrics showing double digit annual growth. These figures provide concrete numbers that investors can weigh against the recent share price moves.

With the share price at US$470.99, Intuitive Surgical’s short term share price return has been weak compared with its longer term record. The 3 year total shareholder return of 55.4% and 5 year total shareholder return of 62.9% show that longer holding periods have looked very different to recent months.

If you are comparing Intuitive Surgical with other healthcare technology names, it could be useful to see what else is moving and review 32 healthcare AI stocks

So with Intuitive Surgical posting double digit revenue and net income growth while the share price has pulled back over the past year, are you looking at a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 11.5% Undervalued

According to the most followed narrative on Intuitive Surgical, the fair value estimate of $532.46 sits above the recent close at $470.99, which frames the current pullback in a very different light for long term holders.

Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue Growth p.a.: 12% (Currently at 14.7%). We saw the peak of revenue growth with nearly 15%. Now even 12% is sporty, but with the “subscription-like” revenues from spare parts and software licences, based on a still growing base of installed systems, realistic. Profit Margin: 30% (currently at 28.6%), because spare parts in general have more margin than system sales, and the sales out of spare parts is still growing. Future PE: 50 (currently at 69). High PEs are typical for fast growers, but over time the PE will go down. I see for the next 5 years 50, in 10 years it could come down to 40. Interest rate: 6.77% (same as current). This leads to an FV of 533 USD, which means ISRG trades with 0.5% at fair value.

Want to see what sits behind that fair value number? The narrative leans on steady revenue expansion, firmer margins and a premium profit multiple that still compresses over time. Curious how those moving parts combine into one price target and what that implies for returns if the story plays out as outlined? The full narrative joins those assumptions together so you can judge if they stack up.

Result: Fair Value of $532.46 (UNDERVALUED)

However, that narrative could be challenged if procedure volumes soften or if competing robotic platforms pressure pricing and the assumed future P/E of 50.

Another View: Rich Multiples Raise the Bar

That fair value narrative points to an 11.5% undervaluation, but the current P/E of 56x tells a different story. It sits well above the Medical Equipment industry at 25x and peers at 28.2x, and it also exceeds a fair ratio of 35.6x. This points to meaningful valuation risk if growth or sentiment cool.

For a closer look at what this high P/E gap could mean in practice, see how the numbers stack up in our valuation breakdown, including the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and concern in this article highlights how split sentiment can be. Take a moment to review the data, stress test your own assumptions, and then weigh those positives against your risk tolerance with the help of the 3 key rewards.

Looking for more investment ideas?

If this kind of detailed breakdown helps you think more clearly about Intuitive Surgical, do not stop here. Fresh opportunities across sectors could strengthen your whole portfolio.

• Target potential mispriced opportunities by scanning a curated set of 53 high quality undervalued stocks that pair quality fundamentals with attractive entry points.
• Lock in income potential by reviewing 13 dividend fortresses built around higher yield companies that still focus on resilience and consistency.
• Dial back volatility risk by filtering for 73 resilient stocks with low risk scores that keep financial strength and stability front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.